Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Portfolio Pulse from Benzinga Newsdesk
Biomea Fusion, Inc. (NASDAQ:BMEA) announced long-term data from its Phase II COVALENT-111 study on BMF-219 for Type 2 Diabetes, showing up to 1.4% HbA1c reduction off therapy at week-26. The data will be presented at the ATTD conference in Florence, Italy.

March 06, 2024 | 8:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomea Fusion's BMF-219 shows promising results in Type 2 Diabetes with up to 1.4% HbA1c reduction off therapy at week-26.
The positive long-term data from the COVALENT-111 study on BMF-219, presented by Biomea Fusion, indicates a significant advancement in the treatment of Type 2 Diabetes. This could potentially lead to increased investor confidence and a positive impact on BMEA's stock price in the short term, as it demonstrates the company's progress in developing effective treatments for metabolic diseases.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100